Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Celyad is a biotechnology business based in the US. Celyad shares (CYAD) are listed on the NASDAQ and all prices are listed in US Dollars. Celyad employs 95 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Robinhood
tastyworks
| Latest market close | $1.29 |
|---|---|
| 52-week range | $0.46 - $3.65 |
| 50-day moving average | $0.99 |
| 200-day moving average | $1.57 |
| Wall St. target price | $8.52 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.51 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.29 from 2023-01-27
| 1 week (2023-01-24) | -19.88% |
|---|---|
| 1 month (2022-12-30) | 161.66% |
| 3 months (2022-10-31) | 22.86% |
| 6 months (2022-07-29) | -24.56% |
| 1 year (2022-01-31) | -63.25% |
|---|---|
| 2 years (2021-01-29) | -84.00% |
| 3 years (2020-01-31) | 10.8 |
| 5 years (2018-01-30) | 47.52 |
| Gross profit TTM | $5,000 |
|---|---|
| Return on assets TTM | -29.33% |
| Return on equity TTM | -92.64% |
| Profit margin | 0% |
| Book value | $1.36 |
| Market capitalisation | $37.2 million |
TTM: trailing 12 months
We're not expecting Celyad to pay a dividend over the next 12 months.
Over the last 12 months, Celyad's shares have ranged in value from as little as $0.46 up to $3.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celyad's is 0.8992. This would suggest that Celyad's shares are less volatile than average (for this exchange).
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. .
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.